PEPD is a pivotal regulator of p53 tumor suppressor

被引:26
作者
Yang, Lu [1 ]
Li, Yun [1 ,2 ]
Bhattacharya, Arup [1 ]
Zhang, Yuesheng [1 ,3 ]
机构
[1] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA
[2] Roswell Pk Canc Inst, Dept Urol, Buffalo, NY 14263 USA
[3] Roswell Pk Canc Inst, Dept Canc Prevent & Control, Buffalo, NY 14263 USA
来源
NATURE COMMUNICATIONS | 2017年 / 8卷
关键词
PROTEIN-PROTEIN INTERACTION; GROWTH-FACTOR RECEPTOR; PROLINE-RICH DOMAIN; PROLIDASE DEFICIENCY; SH3; DOMAIN; EXPRESSION; APOPTOSIS; ENZYME; TRANSACTIVATION; CHEMOTHERAPY;
D O I
10.1038/s41467-017-02097-9
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
p53 tumor suppressor responds to various cellular stresses and regulates cell fate. Here, we show that peptidase D (PEPD) binds and suppresses over half of nuclear and cytoplasmic p53 under normal conditions, independent of its enzymatic activity. Eliminating PEPD causes cell death and tumor regression due to p53 activation. PEPD binds to the proline-rich domain in p53, which inhibits phosphorylation of nuclear p53 and MDM2-mediated mitochondrial translocation of nuclear and cytoplasmic p53. However, the PEPD-p53 complex is critical for p53 response to stress, as stress signals doxorubicin and H2O2 each must free p53 from PEPD in order to achieve robust p53 activation, which is mediated by reactive oxygen species. Thus, PEPD stores p53 for the stress response, but this also renders cells dependent on PEPD for survival, as it suppresses p53. This finding provides further understanding of p53 regulation and may have significant implications for the treatment of cancer and other diseases.
引用
收藏
页数:15
相关论文
共 59 条
  • [1] EVH 1 domains: structure, function and interactions
    Ball, LJ
    Jarchau, T
    Oschkinat, H
    Walter, U
    [J]. FEBS LETTERS, 2002, 513 (01) : 45 - 52
  • [2] The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells
    Baptiste, N
    Friedlander, P
    Chen, XB
    Prives, C
    [J]. ONCOGENE, 2002, 21 (01) : 9 - 21
  • [3] Mutations in proline 82 of p53 impair its activation by Pin1 and Chk2 in response to DNA damage
    Berger, M
    Stahl, N
    Del Sal, G
    Haupt, Y
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (13) : 5380 - 5388
  • [4] A role for the polyproline domain of p53 in its regulation by Mdm2
    Berger, M
    Sionov, RV
    Levine, AJ
    Haupt, Y
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (06) : 3785 - 3790
  • [5] Bergmann M, 1937, J BIOL CHEM, V117, P189
  • [6] Kinetic and Structural Evidences on Human Prolidase Pathological Mutants Suggest Strategies for Enzyme Functional Rescue
    Besio, Roberta
    Gioia, Roberta
    Cossu, Federica
    Monzani, Enrico
    Nicolis, Stefania
    Cucca, Lucia
    Profumo, Antonella
    Casella, Luigi
    Tenni, Ruggero
    Bolognesi, Martino
    Rossi, Antonio
    Forlino, Antonella
    [J]. PLOS ONE, 2013, 8 (03):
  • [7] Identifying the structure of the active sites of human recombinant prolidase
    Besio, Roberta
    Alleva, Stefania
    Forlino, Antonella
    Lupi, Anna
    Meneghini, Carlo
    Minicozzi, Velia
    Profumo, Antonella
    Stellato, Francesco
    Tenni, Ruggero
    Morante, Silvia
    [J]. EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS, 2010, 39 (06): : 935 - 945
  • [8] p53 ubiquitination: Mdm2 and beyond
    Brooks, CL
    Gu, W
    [J]. MOLECULAR CELL, 2006, 21 (03) : 307 - 315
  • [9] Requirement for p53 and p21 to sustain G2 arrest after DNA damage
    Bunz, F
    Dutriaux, A
    Lengauer, C
    Waldman, T
    Zhou, S
    Brown, JP
    Sedivy, JM
    Kinzler, KW
    Vogelstein, B
    [J]. SCIENCE, 1998, 282 (5393) : 1497 - 1501
  • [10] Enhanced prolidase activity and decreased collagen content in breast cancer tissue
    Cechowska-Pasko, Marzanna
    Palka, Jerzy
    Wojtukiewicz, Marek Z.
    [J]. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2006, 87 (04) : 289 - 296